Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

  • STATUS
    Recruiting
  • End date
    Dec 8, 2025
  • participants needed
    30
  • sponsor
    Andrew Hendifar, MD
Updated on 8 December 2021

Summary

The objective of this study is to assess weight stability, functional changes, and quality of life when Pancreaze (pancrelipase) delayed-release 84,000-lipase units (capsules), for main meals, and 42,000-lipase units (capsules), for snacks, are added to standard of care in patients with exocrine pancreatic insufficiency due to pancreatic adenocarcinoma. This will be the first prospective study of this particular formulation in addition to standard of care in advanced pancreatic cancer patients. We will treat 45 consecutive patients with borderline resectable, locally advanced and advanced pancreatic cancer patients who present with weight loss and exocrine pancreatic insufficiency with this advanced formulation of Pancreaze.

Details
Condition Pancreatic Adenocarcinoma
Treatment pancrelipase
Clinical Study IdentifierNCT04098237
SponsorAndrew Hendifar, MD
Last Modified on8 December 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Borderline resectable, locally advanced, and advanced pancreatic cancer patients (can include new or recurrent diagnosis) referred to SOCCI-CSMC
Age 18 years
ECOG performance status 0-1 or Karnofsky PS >60%
Clinical diagnosis of exocrine pancreatic insufficiency
Cachexia defined as at least 5% weight loss in the presence of chronic illness, within any 6-month period prior to screening OR as documented by the medical physician based on standard diagnosis of cachexia
Life expectancy of greater than 3 months, in the opinion of the investigator
Patients must have normal organ and marrow function as defined below
Absolute Neutrophil Count (ANC) 500/mcL
Platelets 50,000/mcL
Total bilirubin 5X upper limit of normal (ULN)
AST(SGOT)/ALT(SGPT) 5 X ULN
Creatinine OR creatinine clearance 3 times the upper limit of normal OR 30 mL/min/1.73 m for patients with creatinine levels above normal
Note: Patients with biliary stents are eligible provided that all other inclusion criteria are met
Woman of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time of signing the informed consent form, for the duration of study participation, and for at least 30 days after discontinuing from study treatment
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Women who are pregnant or are breastfeeding
Dementia or altered mental status that would prohibit the understanding or rendering of informed consent
Unable to swallow intact capsules
Fibrosing colonopathy: Patients with history of fibrosing colonopathy have been reported to experience advancement to colonic strictures with doses of lipase>6000 units/kg/meal over prolonged periods of time
History of chronic illness associated with malabsorption or nutrient deficiency including but not limited to chronic pancreatitis, cystic fibrosis, celiac disease, Crohn's disease, pernicious anemia and/or prior intestinal resection
Coexistent other primary malignancy
Pregnancy, breastfeeding, or of childbearing potential and not willing to use methods of birth control during the study
Active drug abuse or intoxication with any substance including alcohol (blood alcohol content >0.08%, legal driving limit)
Known allergy to any of the active ingredients in pancreatic enzyme supplementation
Concurrent use of pancreatic enzyme supplementation or over the counter supplements which contain lipase, protease, and amylase as active ingredients
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note